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Introduction
Obesity in children and adolescence is on the increase
due to changes in lifestyle and nutrition behaviors (1).
Children who used to play outdoors in the past years are
today more likely to spend their time in front of television
and computer screens. It is known that 1/3 of obese 
children and 80% of obese adolescents remain obese when
they reach adulthood (2). The World Health Organization
(WHO) defines obesity as ‘‘abnormal or excessive fat 
accumulation that presents a risk to health’’ (3). Obese 
children are also more prone to have metabolic syndrome
(MS), type 2 diabetes, hypertension, hyperlipidemia, 
cardiovascular disease and some types of cancer (colon,
breast, gallbladder, endometrium) (4).
A set of risk factors associated with obesity and insulin
resistance lead to chronic changes in various tissues 
and organs. There are racial differences in the prevalence 
of obesity and in the prevalence of obesity-related 
health complications. Although it is known that accurate
management of  MS is fundamental in controlling  the 
current global epidemics of cardiovascular disease and 
diabetes mellitus, the predisposing risk factors or epidemiologic
characteristics of MS are not yet clearly defined in children
and adolescents (5).
The prevalence of MS in different countries has been
reported to be 3-4% (6). Reports from different provinces in
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3%, while it may be as high as 20-38% in obese children
(7,8,9,10). In a recent study, the MS prevalence based on
the International Diabetes Federation (IDF) guidelines was
reported to be 2.3% in the total population. The prevalence
was found to be similar by both IDF and National
Cholesterol Education Program (NCEP) definitions, but 
it was higher when assessed according to the WHO 
definition (11). 
Although there is an increasing number of reports
regarding childhood MS, there is still no universal 
agreement on which level, and even which criteria, should
be used for the diagnosis of MS. The most commonly
applied criteria recommended for use in comparative 
studies are the modified WHO, Cook and the IDF consensus
criteria (12,13). The aim of this study was to determine the
prevalence of and risk factors for MS in obese children and
to compare the three definition criteria for the diagnosis of
MS in children and adolescents.
Methods
Sixty hundred and thirty-five obese children and 
adolescents aged between 7 and 18 years were recruited
from obese children who presented to the Pediatric
Endocrinology Unit. The children were required to meet the
following inclusion criteria: (1) age, 7-18 years; (2) a BMI
greater than the 95th percentile for age and gender based
on the standards of the Centers for Disease Control and
Prevention (CDC); (3) absence of a prior major illness,
including type 1 or 2 diabetes. Being on medications or 
having a condition known to influence body composition,
insulin action or insulin secretion (e.g. glucocorticoid 
therapy, hypothyroidism and Cushing’s disease) was a 
reason for exclusion. Twenty-one cases were excluded due
to inadequacy of the information in their files. Thus, 614
obese children (307 girls and 307 boys) were included in 
the study. 
The mean age of the group was 11.3±2.5 years (range:
7-18 years) and the mean body mass index standard 
deviation score (BMI-SDS) was 2.57±0.59.  Data on age,
gender, birth weight, and feeding in the first 6 months
(regarding exclusive breast-feeding) were obtained 
from the medical records. Cardiovascular disease, type 2
diabetes, obesity and hypertension in the family (first and
second degree relatives) were also recorded from the
specifically asked questions in the patient reports.
Height and weight were measured by the same 
pediatrician. Height was measured to the nearest 0.5 cm on
a standard height board, and weight was determined to the
nearest 0.1 kg on a standard physician’s beam scale with
the subject dressed only in light underwear and no shoes.
BMI was calculated as weight in kilograms divided by
height in meters squared. All measuring devices were
weekly calibrated. Weight SDS, height SDS, BMI, and 
BMI-SDS were calculated for all patients. The degree of
obesity was quantified using the Cole’s least mean square
method, which normalizes the BMI skewed distribution and
expresses BMI as an SDS (BMI-SDS). This measure gives
age- and sex-specific estimates of the distribution median,
the coefficient of variation and the degree of skewness by
a maximum-likelihood fitting technique. Obesity was
defined as a BMI-SDS ≥1.64. Percentile and SDS 
assessments of weight, height and BMI were 
made according to the standards of the CDC (14). Waist 
circumference was measured at the level of the umbilicus
with the patient standing and breathing normally. Pubertal
maturation was evaluated according to Tanner stages (15).
Blood pressure was measured with the auscultatory
method using appropriate cuff, in the fasting state and after
20 minutes of rest. Values over 90th percentile according to
the age, sex and height tables were considered high (16).
Biochemical Definitions and Insulin Sensitivity
Check Indices
Plasma glucose, insulin and lipid levels were measured
in blood samples obtained in the morning by venipuncture
after an overnight fast. Thyroid, liver and kidney functions
were also assessed.  In patients who were found to have a
fasting blood glucose (FBG) level of >100 mg/dL, an 
oral glucose tolerance test (OGTT) was conducted in 
the morning, after an overnight fast, using a dose of 1.75 g
glucose/kg body weight (to a maximum of 75 g) Venous
blood samples were obtained at 0, 30, 60, 90 and 120
minute to measure plasma glucose and insulin levels. 
After clotting, the serum was separated and immediately
subjected to analysis. The patients were defined as having
“impaired glucose tolerance” or “diabetes”, if the glucose
level was between 140-200 mg/dL or >200 mg/dL, 
respectively, in the 2nd hour of the OGTT. 
Hyperinsulinism was defined according to the pubertal
stage: prepubertal >15 mU/L; midpuberty (stages 2-4) >30
mU/L (17). Homeostasis model assessment-insulin 
resistance (HOMA-IR) was calculated according to the 
formula proposed by Levy et al (18): 
HOMA-IR=Fasting insulin (mUI/mL) X fasting glucose
(mmol/L)/22.5 
Plasma concentrations of total cholesterol, high-density
lipoprotein-cholesterol (HDL-cholesterol), low-density
lipoprotein-cholesterol (LDL-cholesterol), triglycerides and
blood glucose were measured using routine enzymatic
methods. Fasting HDL-cholesterol and LDL-cholesterol 
levels were evaluated based on the modified definition 
criteria of the WHO, Cook and the IDF consensus, and
were defined as high, normal or low according to age 
and sex percentiles (12,13,19). HbA1c was measured by
boronic acid affinity chromatography method. 
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MS was defined based on the modified WHO 
criteria adapted for children. The subjects were diagnosed
as having MS if they met 3 of the following 4 WHO criteria
(19): (1) obesity (BMI >95th percentile for age and sex); (2)
abnormal glucose homoeostasis (fasting hyperinsulinemia,
impaired fasting glucose, or impaired glucose tolerance); (3)
hypertension (systolic blood pressure >95th percentile for
age, sex and height); and (4) dyslipidaemia [high 
triglycerides  (>105 mg/dL in children <10 years of age and
>136 mg/dL in children ≥10 years of age), low HDL-
cholesterol (<35 mg/dL) or high total cholesterol (>95th
percentile)]. 
The risk factors were evaluated according to the 
modified WHO criteria.
The patients were also assessed with the modified
Cook criteria (12) and diagnosed as MS if they met at least
three of the conditions listed below: (1) triglyceride 
level >110 mg/dL; (2) HDL-cholesterol level <40 mg/dL;  (3)
fasting blood glucose >110 mg/dL; (4) waist circumference
>90th percentile for age and sex [normal values for Turkish
children (20) were used to assess waist circumference];
and (5) systolic and diastolic blood pressures >90th
percentile according to age, sex and height.
The IDF definition of MS for children aged 10 years or
older includes BMI>90th percentile for age and sex and
presence of two or more of the following findings: (1)
triglycerides >150 mg/dL; (2) HDL-cholesterol <40 mg/dL;
(3) systolic blood pressure >130 mmHg, diastolic >85
mmHg; and (4) plasma glucose >5.6 mmol/L or >100 mg/dL
or known type 2 diabetes (13). 
S St ta at ti is st ti ic ca al l   A An na al ly ys si is s
Statistical analyses were performed by SPSS (Statistical
Package for Social Sciences) for Windows 15.0 (SPSS Inc.,
Chicago, IL) program. The data were presented as
mean±standard deviation (SD) values. Chi-square test and
student’s t-test were used to compare the ratios and the
means of the groups, respectively. A p-value of less than
0.05 was considered statistically significant.
Results
According to the modified WHO criteria, 240 of the 614
patients (39%) were diagnosed with MS. The subjects
were between 7 and 18 years of age and after reevaluation
with the modified Cook criteria, MS was detected in 209 of
them (34%). There were 408 patients aged between 10 and
16 years, of whom 127 (31%) had MS according to the 
IDF-2007 criteria for children and adolescents. The subjects
with a WC>90th percentile constituted 38% of the cases
who were below 10 years of age (n=76/198). The overall
prevalence of MS in our population according to the IDF 
criteria was 33%.
The clinical and metabolic characteristics of the patients
are listed in Table 1. BMI-SDS values in the obese males
were significantly higher than those in the females and,
males were predominant among MS patients (p<0.001).
Although all HbA1c levels were within the normal reference
range, males had significantly higher HbA1c levels than
females (p=0.006). 
Mean age, BMI-SDS and weight to height (W/H) ratio of
the patients with MS were significantly higher than those of
the non-MS patients. In Table 2, MS and non-MS 
obese patients are compared according to their metabolic
characteristics, anthropometric measurements and risk 
factors for MS. 
The proportion of patients who had high triglyceride and
total cholesterol levels were 82% and 18% in the MS
group, while these rates were 31% and 15% in the non-MS
group. There was a statistically significant difference
between the two groups for triglyceride levels (p<0.05), but
not for total cholesterol (p>0.05). 
Impaired fasting plasma glucose was detected in 74 out
of 240 patients who had MS vs. 17 of 374 non-MS obese
patients (p>0.05). Twelve patients had impaired glucose 
tolerance and 9 of these (75%) had MS.
In 345 patients (56%) who were defined as severely
obese, BMI-SDS was above 2.5. The mean age of 
the severely obese patients was comparable to that of the
subjects who were not severely obese (11.2±2.5 vs.
11.4±2.5 years, p>0.05). MS was detected in 24%
(n=65/269) and 51% (n=175/345) of obese and severely
obese patients, respectively (p<0.05) (Figure 1A).
The numbers of family members who had cardiovascular
disease, type 2 diabetes, obesity or hypertension were 
significantly higher in patients with MS (p<0.05) (Figure 1B).
MS was detected in 34% (n=89/259) of children who were
exclusively breastfed in the first 6 months of life, while this
rate was 52% (n=111/212) in children who were never
breastfed (p<0.05) (Figure 1C). There was no significant 
difference between the birth weights of MS and non-MS
patients (Table 2).
When the patients were divided into age groups as 7-11
years (n=344) and 12-18 years (n=270), the prevalence of
MS was found to be significantly higher in the second
group (114/344 vs. 126/270, p=0.00). Thirty percent
(n=90/296) of the prepubertal patients were diagnosed with
MS vs. 47% (n=150/318) of the pubertal patients (p<0.05)
who were above 7 years old (Figure 1D).
Fasting plasma glucose, triglycerides, HDL-cholesterol,
LDL-cholesterol, HbA1c, fasting insulin, and HOMA-IR
index of the pubertal and non-pubertal cases are shown in
Table 3. 
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MS is a cluster of risk factors which is becoming more
prevalent concurrent with obesity. Although the prevalence
figures differ by diagnostic criteria, the overall prevalence is
estimated to be 3-4% (21). According to Cizmecioglu et al
(10), 38.8% of obese children in Turkey were diagnosed 
as having MS based on the WHO criteria, whereas the
prevalence declined to 24% when the International
Cholesterol Education Panel (NCEP) criteria were 
used. Miranda et al (22) reported from USA that the MS
prevalence was 22% by NCEP criteria, while Isomaa et al
(23) found this prevalence to be 42% based on the WHO
criteria. In the present study, using the modified WHO 
criteria, the prevalence of MS was 39% in 614 obese
patients between 7 and 18 years of age. When these same
patients were reevaluated with the modified Cook criteria,
the MS prevalence decreased to 34%. In addition, we
found that 31% of the children aged 10-16 years met the
criteria for MS based on the pediatric MS definition of the
IDF consensus. The overall prevalence with IDF criteria was
33% and this prevalence was lower than that obtained by
other criteria. These different results indicate the necessity
to conduct more studies in this field and to revise the 
diagnostic criteria. 
In relevance to our study, we attempted to present an
overview of previous reports on the prevalence of MS in
Turkey. Kelestemur et al (7) reported from Kayseri that the
prevalence of MS in obese children was 20%. In a study
conducted in Ankara city, 4.9% of the 1385 children
between 10 and 17 years were obese, and the prevalence
of MS in this obese population was estimated to be 21%
(8). Atabek et al (9) identified the MS in 27.2% of obese 
children and adolescents in Konya city.  In our study, the
prevalence of MS according to the WHO criteria was 
similar to that reported by Cizmecioglu et al (11) (39% vs.
38.8%), but higher as compared to the results of the 
previous studies cited above. This finding can be interpreted
as a consequence of the gradually increasing prevalence of
MS in children or indicates specific genetic or environmental
characteristics of the population in different regions 
of Turkey. Climate, culture and dietary behaviors are known
to vary significantly among the different regions of the 
country. Meat products and high-fat-containing meals are
extensively consumed in some regions, while vegetables
and vegetable oil constitute an important food item in other
regions. Cold and long winters shorten the duration of 
outdoor games and enforce the children to a sedentary
lifestyle. We consider that these factors affect the 
MS prevalence as well as the severity and prevalence of
obesity in the different regions. 
In this study, the prevalence of MS was significantly
higher in the group which was between 12 and 18 years of
age and in the pubertal group. Atabek et al (9) also found
that 20% of obese children and 37.6% of adolescents have
evidence of MS; however, their patients were not evaluated
for pubertal status. There are many reports on the risk 
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Figure 1A. MS prevalence was 24% and 51% in obese patients who
have BMI-SDS<2.5 and BMI-SDS>2.5, respectively (p<0.5)
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Figure 1B. MS prevalence was 22% and 52% in the patients who do
not have and  have family risk factors, respectively (p<0.5)
Figure 1C. MS prevalence was 34% and 52% in the patients who
were exclusively or never breastfed, respectively (p<0.5)
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Figure 1D. MS prevalance was 30% and 47% in prepubertal and
pubertal patients, respectively (p<0.5)
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nfactors for MS and, particularly, on insulin resistance, BMI
and puberty. It has been shown that when the adjusted
insulin resistance according to ethnic origin and the degree
of obesity increase, the prevalence of MS also increases
(23). A prospective study investigating the cardiovascular
risk factors in Finn youth has shown that MS develops in
those with high initial insulin levels (24). On the other hand,
according to the data of the Bogalusa Heart Study, high
BMI, independently from insulin resistance, increases the
risk of MS (25). Costa et al (26) observed an association
between BMI percentile and a cluster of cardiovascular 
risk factors, such as increased blood pressure, low HDL-
cholesterol, increased triglyceride levels, increased insulin
levels, as well as insulin resistance. Pilia et al (27) studied
the effect of puberty on insulin resistance and found that
the increase in HOMA-IR in obese children at puberty is
greater than that in normal-weight children. In this study,
we observed significantly higher MS rates in patients in the
pubertal group who had high triglyceride, low HDL-
cholesterol and high fasting insulin levels as well as high
HOMA-IR index and similar BMI-SDS values with prepuber-
tal patients.  Although MS patients have significantly higher
BMI-SDS than non-MS patients, puberty is suggested to be
one of the major predisposing factors of MS, irrespective of
BMI. 
Osei et al (28) demonstrated that within normal HbA1c
limits, there were several anthropometric and metabolic 
differences among high-risk African-Americans for type 2
diabetes, belonging to the lower and upper HbA1c tertiles.
Although all HbA1c levels were in the normal reference
range, males had significantly higher HbA1c levels 
than females in our study. This can be associated with the
significantly higher BMI-SDS of the males. Even though the
difference is not statistically significant, boys are more
prone to be diagnosed with MS, which probably is the
result of their higher BMI-SDS and HbA1c levels. However,
HOMA-IR values in the females were higher than in males
although their BMI and HbA1c levels were lower. It is 
difficult to interpret these findings and to state that they
result from the slightly higher insulin levels of females, a
finding which was not statistically significant.
Sen et al (29) reported that MS was diagnosed in 38.7%
and 49.7% of obese (BMI-SDS: 2-2.5) and severely obese
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Table 1. Clinical characteristics and laboratory parameters of the study
population (mean±SD values) 
Total group Males Females p
n= 614  n= 307 n= 307
Age (years) 11.3±2.5 11.3±2.37 11.29±2.64 0.78
BMI-SDS 2.57±0.59 2.71±0.55 2.43±0.59 0 0. .0 00 00 0
Birth weight (g) 3383±709.3 3435±755.3 3332.3±657.5 0.09
Breastfed (n) 260 127 133 0.81
Fasting glucose  90.9±13.5 91.4±8.4 90.4±17.1 0.33
(mg/dL)
Fasting insulin  17.6±10.6 16.8±9.68 18.6±11.5 0.64
(mIU/mL)
HDL-cholesterol 44.6±10.69 45±11.2 44.2±10.1 0.37
(mg/dL)
LDL-cholesterol 96.5±29.2 98.2±30.3 94.8±27.9 0.19
(mg/dL)
Triglycerides 130.78±69.3 130.7±71.2 130.7±67.6 0.99
(mg/dL)
HbA1c (%) 5±0.75 5.15±0.68 4.95±0.82 0 0. .0 00 06 6
HOMA-IR 3.39±2.07 3.18±1.77 3.63± 2.35 0 0. .0 01 16 6
Hypertension(n) 232 128 104 0.42
Diagnosed MS* 240 130 110 0.1
*MS: Metabolic syndrome diagnosed according to the modified WHO criteria
HOMA-IR: homeostasis model assessment for insulin resistance (fasting insulin
(mIU/mL) X fasting glucose (mmol/L) /22.5, BMI-SDS: body mass index-standard
deviation score 
Table 2. Comparison of risk factors, metabolic characteristics and 
anthropometric measurements in MS* and non-MS obese patients
(mean±SD values and percentages)
MS non-MS P
n= 240 n=374
Age (years) 11.8±2.32 11±2.57  0 0. .0 00 0
BMI SDS 2.85±0.55 2.39± 0.54 0 0. .0 00 0
Weight for height 160.2±20.7 142.6±13.5 0 0. .0 00 0
Birth weight (g) 3419.1±630.1 3360.7±756.5 0.35
Fasting glucose (mg/dL) 93.4±19.1 89.2±7.4 0 0. .0 00 0
HDL-cholesterol (mg/dL) 38.4±7.6 49.4±10.2 0 0. .0 00 0
LDL-cholesterol (mg/dL) 96.7±32 96.4±27.3 0.93
Triglycerides (mg/dL) 171.7±69.7 103±53.8 0 0. .0 00 0
HOMA-IR 3.93±2.28 3.03±1.8 0 0. .0 00 0
HbA1c (%) 5.2±0.79 4.96±0.72 0 0. .0 00 0
Breastfed (n) 89 (37%) 170 (45%) 0 0. .0 00 0
Pubertal (n) 150 (63%) 168 (45%) 0 0. .0 00 0
Family history for diabetes 176 (73%) 158 (42%) 0 0. .0 00 0
(n, %)
*According to the WHO criteria; MS: metabolic syndrome
HOMA-IR: homeostasis model assessment for insulin resistance
BMI-SDS: body mass index-standard deviation score adolescents (BMI-SDS>2.5), respectively. The prevalence
of MS was determined as 28.7% in obese adolescents
(BMI percentile>95th percentile) in another study, while it
was 6.8% in overweight adolescents (BMI: 85-95th 
percentile) (12). Similarly, MS was detected with a preva-
lence of 24% and 52% in our obese and severely obese
patients. These findings indicate a linear correlation
between MS and severity of obesity.  
MS risk is reported to be higher in children of families
who have diabetes, heart disease, hypertension and 
disturbance of lipid metabolism (30,31). We also found that
the prevalence of MS is significantly higher in the children
who have a family member with diabetes, hypertension,
coronary artery disease or hyperlipidemia (Figure 1B). This
can be attributed to the effect of genetic factors, but also
may indicate similar environmental conditions, dietary
habits, socioeconomic status and sedentary lifestyle.
Breast milk is found to be protective against some 
components of MS (32). It has been reported that the
prevalence of obesity increases two-fold in children who
were not breastfed as compared to breastfed children, with
a concurrent increase in MS prevalence (33). However,
Kelishadi et al (34) stated that breast milk has no protective
effect against MS, but did not give any data on MS 
prevalence in non-breastfed children. In our study, the MS
prevalence was significantly higher in the non-breastfed
group. This result supports the idea that breast milk has a
protective effect against obesity and, indirectly, against MS.
Some studies demonstrate that children who have low
and high birth weight or a high weight gain in the early 
postnatal period are at higher risk of developing obesity and
MS in older ages, while other studies found that neither
gestation week nor birth weight is associated with MS
(35,36,37). Our results showed no significant correlation
between MS and birth weight and supported the reports
stating that birth weight is not being related to MS.
However, further studies, particularly comparing children
with high or low birth weights, are required to get more
conclusive results on the relationships between birth
weight and MS.
In conclusion, in parallel to the obesity epidemic, the
prevalence of the MS in children and adolescents shows an
alarming increase, becoming a growing problem in 
childhood. Severe obesity, age, pubertal status, presence
of family history of cardiovascular disease, type 2 diabetes,
obesity or hypertension and not being breastfed during
infancy appear to be important risk factors associated with
MS in childhood. Further studies are needed to revise the
diagnostic criteria in childhood and to reach a consensus on
the diagnosis of MS.
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